secwatch.observer — SEC 8-K summary
======================================

Issuer:     RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK:        0001649904
Form:       8-K
Filed at:   2025-02-26T23:59:59+00:00
Accession:  0001558370-25-001553
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rhythm Q4 2024 IMCIVREE revenue $41.8M; cash runway extended to 2027
--------------------------------------------------------------------

- Q4 2024 IMCIVREE net revenue $41.8M (+26% sequential, +73% YoY); FY2024 total $130.1M.
- Net loss Q4 2024 ($44.6M) or ($0.72)/share vs ($41.6M) in Q4 2023; FY loss ($264.6M).
- Raised ~$75M gross proceeds from ATM (1.3M shares at ~$56.30); cash $320.6M at Dec 31, 2024.
- FDA and UK MHRA expanded IMCIVREE label to children as young as 2 years old.
- Phase 3 acquired hypothalamic obesity trial topline data expected Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649904/000155837025001553/0001558370-25-001553-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649904/000155837025001553/rytm-20250226x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-001553

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer